Tadalafil Tablet
Product Images NDC 71335-1823

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1823). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351823)

Label for Tadalafil 2.5 mg oral tablets packaged by Bryant Ranch Prepack. The label mentions the product is a generic equivalent to Cialis 2.5 mg tablets by Ajanta Pharma Limited. It includes storage instructions for room temperature (20°-25°C), a warning to keep drugs out of reach of children, and the NDC 71335-1823. The label also indicates a quantity of 90 tablets.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The graph shows greater score reduction with Tadalafil over time versus placebo, with data points at 0, 2, 4, 8, and 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing blood pressure changes over time in hours. The graphs plot the difference in systolic and diastolic blood pressure (mmHg) between tadalafil and placebo groups, for both standing and supine positions, up to 96 hours post-dose.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing changes in systolic blood pressure (mmHg) over time (hours post-dose) for Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The top graph presents standing systolic blood pressure, and the bottom graph presents supine systolic blood pressure, depicting blood pressure trends up to 24 hours post-dose.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, combined with doxazosin. The x-axis shows time in hours post-administration, and the y-axis shows systolic blood pressure changes in mmHg. Four groups are compared: 20 mg tadalafil at 08:00 plus 8 mg doxazosin at 08:00, placebo at 08:00 plus 8 mg doxazosin at 08:00, 20 mg tadalafil at 20:00 plus 8 mg doxazosin at 08:00, and placebo at 20:00 plus 8 mg doxazosin at 08:00, each represented by distinct line styles and markers.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph illustrates changes in concentration with error bars across a 120-hour period.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment, comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline scores, with Tadalafil demonstrating a greater decrease than placebo, reaching statistical significance (p<0.01).*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph depicting the change from baseline in IPSS Total Score over 12 weeks of treatment, comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in score. Tadalafil shows a greater decrease, with significance noted at p<0.01.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph titled "Weeks of Therapy" showing least squares mean change from baseline over 26 weeks. It compares Tadalafil/Finasteride and Placebo/Finasteride treatments, with Tadalafil/Finasteride indicated by solid lines and Placebo/Finasteride by dashed lines. The graph includes statistical notations for significance (p<0.001 and p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, illustrating its molecular framework with labeled atoms and bonds as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.